TherapeuticsMD, Inc. (TXMD) income statement
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3026% below fair value
$1.81−0.10 (-5.24%)
Close on Nov 18, 2026Market cap $20.95MP/E –Yield –
TherapeuticsMD, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -120.9%
- Net margin
- -6.6%
- Return on equity, FY2025
- -2.1%
Financial strength
- Current ratio
- 3.22
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 183.7%
Valuation
- P/E ratio
- –
- Price to sales
- 6.41
- Price to book
- 0.77
- Dividend yield
- –
See a number that looks wrong?